序号股票简称PE(TTM)PE(静)市净率总市值(元)7诺思格30.4831.132.3443.65亿行业平均 39.5845.743.43155.97亿行业中值40.6052.662.7056.52亿1药明康德16.8719.963.031886.47亿2康龙化成 22.1623.082.95413.96亿3诺泰生物24.1229.264.31118.34亿4普蕊斯25.9622.232.0023.66亿5诺禾致源 27.7928.722.2356.52亿6凯莱英30.0031.411.73298.03亿8爱尔眼科31.1532.475.291154.48亿9华康洁净 35.1736.811.4224.59亿10通策医疗35.5236.294.32181.96亿11昭衍新药36.72192.041.75142.25亿12华厦眼科 37.7437.192.70159.43亿 来源：金融界 资金流向方面，6月26日，诺思格主力资金净流出311.84万元，近5日总体呈流出状态，5日共流出 1968.35万元。 诺思格(北京)医药科技股份有限公司的主营业务是为全球的医药企业和科研机构提供综合的药物临床研 发全流程一 ...

截至2025年一季报，共有12家机构持仓诺思格，其中基金7家、其他5家，合计持股数3279.94万股，持 股市值16.85亿元。 诺思格(北京)医药科技股份有限公司的主营业务是为全球的医药企业和科研机构提供综合的药物临床研 发全流程一体化服务。公司的主要产品是临床试验运营服务、临床试验现场管理服务、数据管理与统计 分析服务、生物样本检测服务、临床试验咨询服务、临床药理学服务。 最新一期业绩显示，2025年一季报，公司实现营业收入1.73亿元，同比-2.53%；净利润2607.37万元，同 比13.12%，销售毛利率36.53%。 6月5日，诺思格今日收盘50.65元，下跌2.61%，滚动市盈率PE（当前股价与前四季度每股收益总和的比 值）达到34.15倍，总市值48.92亿元。 序号股票简称PE(TTM)PE(静)市净率总市值(元)24诺思格34.1534.892.6348.92亿行业平均 40.8246.973.46158.62亿行业中值45.9353.092.7358.93亿1润达医疗-291.25192.732.51106.54亿2何氏眼 科-154.63-134.561.9336.87亿3*ST生物- ...

最新一期业绩显示，2025年一季报，公司实现营业收入15.64亿元，同比-5.79%；净利润1.65亿元，同 比-29.61%，销售毛利率30.03%。 序号股票简称PE(TTM)PE(静)市净率总市值(元)42泰格医药132.44109.682.16444.38亿行业平均 40.8246.973.46158.62亿行业中值45.9353.092.7358.93亿1润达医疗-291.25192.732.51106.54亿2何氏眼 科-154.63-134.561.9336.87亿3*ST生物-126.41-122.8910.3824.39亿4诚达药业-72.40-124.031.6334.86亿5普 瑞眼科-66.27-59.532.8460.64亿6皓宸医疗-52.62-63.296.2423.86亿7创新医疗-47.91-53.502.8550.26亿8国际 医学-44.81-45.063.21114.52亿9百诚医药-38.05-92.881.9248.99亿10金域医学-35.64-36.492.02139.12亿11睿 智医药-26.03-22.344.1550.59亿 来源：金融界 截至2025年 ...

从行业市盈率排名来看，公司所处的医疗服务行业市盈率平均38.49倍，行业中值39.26倍，诺思格排名 第23位。 截至2025年一季报，共有12家机构持仓诺思格，其中基金7家、其他5家，合计持股数3279.94万股，持 股市值16.85亿元。 5月20日，诺思格今日收盘44.6元，上涨1.71%，滚动市盈率PE（当前股价与前四季度每股收益总和的比 值）达到30.07倍，总市值43.08亿元。 最新一期业绩显示，2025年一季报，公司实现营业收入1.73亿元，同比-2.53%；净利润2607.37万元，同 比13.12%，销售毛利率36.53%。 序号股票简称PE(TTM)PE(静)市净率总市值(元)23诺思格30.0730.722.3143.08亿行业平均 38.4944.343.45153.98亿行业中值39.2651.172.7152.70亿1润达医疗-295.54195.572.55108.11亿2何氏眼 科-141.11-122.801.7633.64亿3*ST生物-124.18-120.7310.2023.96亿4诚达药业-70.53-120.841.5933.96亿5普 瑞眼科-68.23-61. ...

截至2025年一季报，共有80家机构持仓泰格医药，其中基金78家、社保1家、其他1家，合计持股数 17066.48万股，持股市值86.71亿元。 杭州泰格医药科技股份有限公司的主营业务是为新药研发提供临床试验全过程专业服务的合同研究组织 （CRO），为全球医药和医疗器械创新企业提供全面而综合的临床研究解决方案。公司的主要产品是 临床运营、临床药理、注册与法规事务、科学事务、医学翻译、药物警戒、真实世界研究、第三方稽查 与培训、数据管理及统计分析、临床试验现场管理、受试者招募、医学影像以及实验室。 5月20日，泰格医药今日收盘45.35元，上涨6.76%，滚动市盈率PE（当前股价与前四季度每股收益总和 的比值）达到116.90倍，总市值392.25亿元。 从行业市盈率排名来看，公司所处的医疗服务行业市盈率平均38.49倍，行业中值39.26倍，泰格医药排 名第42位。 最新一期业绩显示，2025年一季报，公司实现营业收入15.64亿元，同比-5.79%；净利润1.65亿元，同 比-29.61%，销售毛利率30.03%。 序号股票简称PE(TTM)PE(静)市净率总市值(元)42泰格医药116.9096.821. ...

最新一期业绩显示，2025年一季报，公司实现营业收入15.64亿元，同比-5.79%；净利润1.65亿元，同 比-29.61%，销售毛利率30.03%。 序号股票简称PE(TTM)PE(静)市净率总市值(元)42泰格医药112.8393.451.84378.59亿行业平均 37.7943.763.40151.99亿行业中值38.8551.492.7248.17亿1润达医疗-303.46200.812.62111.01亿2何氏眼 科-136.34-118.641.7032.51亿3*ST生物-121.10-117.739.9523.37亿4普瑞眼科-68.82-61.822.9562.97亿5诚达 药业-68.70-117.701.5433.08亿6皓宸医疗-50.22-60.405.9622.76亿7国际医学-45.99-46.253.29117.54亿8创新 医疗-42.40-47.342.5244.48亿9金域医学-36.70-37.582.08143.29亿10百诚医药-29.24-71.391.4737.65亿11迪 安诊断-23.32-26.201.4393.62亿 来源：金融界 截至2025年一季 ...

诺思格(北京)医药科技股份有限公司的主营业务是为全球的医药企业和科研机构提供综合的药物临床研 发全流程一体化服务。公司的主要产品是临床试验运营服务、临床试验现场管理服务、数据管理与统计 分析服务、生物样本检测服务、临床试验咨询服务、临床药理学服务。 最新一期业绩显示，2025年一季报，公司实现营业收入1.73亿元，同比-2.53%；净利润2607.37万元，同 比13.12%，销售毛利率36.53%。 序号股票简称PE(TTM)PE(静)市净率总市值(元)23诺思格30.0830.732.3143.09亿行业平均 38.1544.203.39150.89亿行业中值38.4849.482.6651.49亿1润达医疗-308.74204.312.66112.94亿2何氏眼 科-135.81-118.181.6932.38亿3*ST生物-118.02-114.749.7022.77亿4普瑞眼科-70.21-63.073.0164.25亿5诚达 药业-68.67-117.641.5433.06亿6皓宸医疗-50.77-61.076.0223.02亿7国际医学-45.64-45.903.27116.64亿8创新 医疗- ...

Company Overview - Norsg achieved a closing price of 44.77 yuan, down 20.00%, with a rolling PE ratio of 30.84 times and a total market value of 4.324 billion yuan [1] - The company operates in the medical services industry, which has an average PE ratio of 45.72 times and a median of 41.83 times, placing Norsg at the 25th position in the industry ranking [1] Shareholding Structure - As of the 2024 annual report, 112 institutions hold shares in Norsg, including 106 funds and 6 other entities, with a total shareholding of 43.1268 million shares valued at 2.156 billion yuan [1] Business Operations - Norsg specializes in providing comprehensive drug clinical research and development services for global pharmaceutical companies and research institutions, including clinical trial operation services, site management services, data management and statistical analysis services, biological sample testing services, clinical trial consulting services, and clinical pharmacology services [1] Financial Performance - For the 2024 annual report, Norsg reported an operating revenue of 744 million yuan, a year-on-year increase of 3.14%, and a net profit of 140 million yuan, reflecting a year-on-year decrease of 13.73%, with a sales gross margin of 37.09% [1]

Group 1 - The core viewpoint of the news is that Tiger Med's stock price has significantly declined, leading to a high rolling PE ratio compared to the industry average [1] - As of April 7, Tiger Med's closing price was 45.8 yuan, down 10.72%, with a rolling PE ratio of 97.78 times and a total market capitalization of 39.615 billion yuan [1] - The company experienced a net outflow of main funds amounting to 122.997 million yuan on April 7, with a total outflow of 187.169 million yuan over the past five days [1] Group 2 - Tiger Med is primarily engaged in providing comprehensive clinical research solutions as a Contract Research Organization (CRO) for new drug development [1] - The company's latest financial results for the year 2024 show a revenue of 6.603 billion yuan, a year-on-year decrease of 10.58%, and a net profit of 405 million yuan, down 79.99% [1] - The gross profit margin for the company stands at 33.95% [1] Group 3 - In terms of industry comparison, the average PE ratio for the medical services sector is 45.72 times, with a median of 41.83 times, placing Tiger Med at the 38th position in the industry ranking [2] - The industry average market capitalization is 142.68 billion yuan, while the median is 43.24 billion yuan [2]

4月1日，诺思格今日收盘53.0元，上涨3.15%，滚动市盈率PE（当前股价与前四季度每股收益总和的比 值）达到36.51倍，总市值51.19亿元。 从行业市盈率排名来看，公司所处的医疗服务行业市盈率平均52.86倍，行业中值49.90倍，诺思格排名 第26位。 股东方面，截至2025年2月28日，诺思格股东户数5105户，较上次减少336户，户均持股市值35.28万 元，户均持股数量2.76万股。 序号股票简称PE(TTM)PE(静)市净率总市值(元)26诺思格36.5136.512.7951.19亿行业平均 52.8647.733.76166.77亿行业中值49.9041.242.8051.60亿1普瑞眼科-185.3323.162.8062.06亿2何氏眼 科-165.9550.881.6732.33亿3迪安诊断-106.4132.041.4098.50亿4光正眼科-95.73227.447.7121.05亿5创新医 疗-92.46-129.222.4044.30亿6南华生物-89.74-118.0813.3833.27亿7国际医学-35.28-34.303.46126.36亿8嘉和 美康-30.45- ...